The azacitidine plus romidepsin clinical trial in lymphoid malignancies
Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor
Recently approved drugs for the treatment of multiple myeloma
Round table with Prof. John Gribben and Prof. Stephan Stilgenbauer on CLL
John Gribben et al.
TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas